Results 161 to 170 of about 152,752 (282)

Tumor-Infiltrating Lymphocytes Demonstrate Distinct Behavior in the Tumoral and Peritumoral Microenvironment After Neoadjuvant Chemotherapy in Patients with Resected Adenocarcinoma of the Gastric or Gastroesophageal Junction: Results from a Single Center. [PDF]

Cancers (Basel)
Seretis F, Panagaki A, Ritsatou S, Stoupi E, Theodorou A, Smparounis S, Glava C, Theochari M, Triantafyllou T.   +8 more
europepmc   +1 more source

Maximizing Efficacy of Cancer Nanovaccines and Immune Cells Landscape in Responders and Non‐Responders to Immunotherapy

Advanced Science, EarlyView.
To maximize the efficacy of cancer vaccines, adjuvants, collection, lysis, purification, oxidation, loading sites, and sizes, etc., are investigated. The optimized cancer nanovaccines loading whole tumor antigens can cure all or most tumor‐bearing mice in multiple mouse cancer models.
Xiangxiang Xu, Lu Diao, Jin Wang, Ao Zhu, Xianlan Chen, Yan Zheng, Yuhan Liu, Kang Hu, Jiashan Zhu, Cheng Ding, Chang Li, Yunzhi Pan, Jun Zhao, Mi Liu   +13 more
wiley   +1 more source

Localized Delivery of the mRNAs Encoding CD47 Inhibitor and Interleukins 12, 15, and 21 Elicits Robust Antitumor Immunity

Advanced Science, EarlyView.
The co‐delivery of mRNAs encoding a CD47 inhibitor and a cytokine cocktail (interleukins 12, 15, and 21) via lipid nanoparticles enables effective localized immunotherapy. This strategy not only suppresses tumor progression but also enhances type 1 conventional dendritic cell (cDC1) differentiation and activates CD8+ T cells, thereby inducing robust ...
Tao Jiang, Shuaiyang Jing, Haojun Li, Bao Xiao, Jiahui Jin, Xiu Sun, Juan Wang, Jing Liang, Tongze Cai, Huili Hu, Meilan Wei, Xuanrui Zhong, Yang Ji, Peng George Wang, Jianlong Zhou   +14 more
wiley   +1 more source

T lymphocyte heterogeneity in NSCLC: implications for biomarker development and therapeutic innovation. [PDF]

Front Immunol
Liu Y, Qin D, Fu J.
europepmc   +1 more source

STS2 deficiency revives CD8⁺T cells from exhaustion and augments checkpoint blockade efficacy in cancer immunotherapy. [PDF]

J Immunother Cancer
Sun F, Ma F, Wang T, Zhou Y, Xu D, Mo H, Li C, Guo J, Zhao Z, Yang X, Zhong N, Zhang Y, Qian H.   +12 more
europepmc   +1 more source

Label‐Free 3D Photoacoustic Imaging of Tumor Organoids for Volumetric Drug Screening

Advanced Science, EarlyView.
A label‐free organoid photoacoustic imaging (LFOPI) system is developed for precise volumetric drug screening evaluation. As a proof of concept, LFOPI's performance in chemotherapy and immunotherapy drug screening assays are further evaluated. The LFOPI offers unique non‐invasive, label‐free capabilities for tumor organoids, and contributes to the ...
Xiaofei Luo, Maike Chen, Han Shan, Xize Yu, Qibo Lin, Qian Tao, Xiongwei Wei, Changling Lv, Ziyan Chen, Fan Zhuo, Xi Zhu, Jiaxing He, Zhaoxi Li, Chunlong Fei, Jing Xu, Juan Su, Zeyu Chen, Shuang Zhao, Xiang Chen   +18 more
wiley   +1 more source

Evaluation of tumor budding, desmoplastic reaction, and lymphocytic infiltration in predicting survival for pancreatic ductal adenocarcinoma. [PDF]

World J Gastrointest Oncol
Alpsoy A, Yavuz A, Simsek K, Altunay B, Karaca M, Unal B, Bassorgun CI, Tatli AM, Elpek GO.   +8 more
europepmc   +1 more source

Comparative Analysis of Clinical Outcomes and Financial Aspects of Phototherapies and Immunotherapy for Cancer

Advanced Science, EarlyView.
This review compares clinical outcomes, translational progress, and global funding trends across cancer phototherapies—photodynamic, photothermal, and photoimmunotherapy—and conventional immunotherapy. It highlights differences in treatment efficacy, clinical trial status, financial investment, and regulatory challenges, providing a comprehensive ...
Deepak S. Chauhan, Kun Shao, Roopa Hebbandi Nanjundappa, Daniel‐Jiajun Yu, Marianne Stanford, Huile Gao, Channakeshava Sokke Umeshappa   +6 more
wiley   +1 more source

The role of tumor-infiltrating lymphocytes and depth of invasion in T1 bladder cancer: a retrospective analysis. [PDF]

BMC Urol
Yaprak Bayrak B, Dogan HN, Teke K, Yuvak H, Dillioglugil O.   +4 more
europepmc   +1 more source

An Engineered Soluble Single‐Chain TCR Engager for KRAS‐G12V Specific Tumor Immunotherapy

Advanced Science, EarlyView.
This study develops a dimeric T cell receptor engager protein specific for tumor KRAS‐G12V mutation. The engager proteins are capable of mediating the formation of synapse between T cell and tumor cell and demonstrate substantial tumor suppression efficacy.
Keke Ma, Jie Wang, Min Jiang, Juanhua He, Fangyang Li, Dan Lu, Chao Su, Yan Chai, Wenjing Jin, Yu Chen, Catherine W.H. Zhang, Xiaopeng Ma, Hui Tan, George F. Gao, Shuguang Tan   +14 more
wiley   +1 more source